© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
In the Short Term, Most Patients With RA Remain on a Biosimilar Post Switch
The Center for Biosimilars Staff
June 16 2019
During this week’s European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, researchers from the University of Manchester reported on their findings regarding patients with rheumatoid arthritis (RA) involved in the BSRBR-RA study who had switched from reference infliximab or reference etanercept to biosimilars.
Biosimilar Adalimumab, Hulio, Is Safe Long-Term, Causes Less Injection-Site Pain Than Humira
Kelly Davio
June 14 2019
During this week’s European League Against Rheumatism Annual European Congress of Rheumatology, researchers will present on the long-term safety, immunogenicity, and efficacy of the biosimilar versus the reference in an open-label extension study that involved switching between the biosimilar and the reference.
Real-World Data on SB4 Highlight Biosimilar Etanercept's Efficacy
Kelly Davio
June 12 2019
During this week’s European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, multiple teams of researchers will present their findings on real-world evidence of the biosimilar’s efficacy and the feasibility of switching to SB4 from the reference etanercept, Enbrel.
Amgen's Trastuzumab Biosimilar, Kanjinti, Clinically Similar to Herceptin in Cardiac Safety
Kelly Davio
June 6 2019
During this week’s 2019 American Society of Clinical Oncology Annual Meeting, researchers reported on the cardiac safety of Amgen’s biosimilar trastuzumab, ABP 980 (approved in the European Union under the name Kanjinti), versus the reference trastuzumab, Herceptin.
Developers Provide Updates on 3 Biosimilar Pegfilgrastim Programs
The Center for Biosimilars Staff
June 5 2019
Multiple biosimilars of pegfilgrastim are available in both the United States and Europe, and the field of competitors to Amgen’s brand-name Neulasta continues to expand. During the 2019 American Society of Clinical Oncology Annual Meeting, 3 research teams shared their findings on biosimilar pegfilgrastim development programs from sponsors Sandoz, Fresenius Kabi, and Gema Biotech.
Real-World Data Underscore the Safety and Highlight the Acceptance of Biosimilar Rituximab
Kelly Davio
June 4 2019
While no biosimilar rituximab products have yet become available in the United States, biosimilar rituximab products are available in the European Union, and data on their use, published concurrently with the 2019 American Society of Clinical Oncology Annual Meeting, highlight not only their safety but also their growing acceptance among prescribers in Europe.
Phase 3 and Postmarketing Data Support the Efficacy and Safety of Biosimilar Trastuzumab, Ogivri
Kelly Davio
June 4 2019
During this week’s 2019 American Society of Clinical Oncology Annual Meeting, researchers presented the final overall survival results from the phase 3 HERITAGE study of biosimilar trastuzumab, Ogivri. In addition, another research group shared its findings on postmarketing surveillance of Ogivri in Brazil.
Biosimilar Pegfilgrastim Can Increase Access, but Patient Perception Remains a Biosimilar Barrier
Kelly Davio
June 3 2019
During the 2019 American Society of Clinical Oncology Annual Meeting, researchers said that, for payers with large populations, the discounted biosimilar pegfilgrastim can produce substantial cost savings that can be applied to offer increased access to supportive care.